Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Cancer Vaccines and Antibodies

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4515
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Cancer Vaccines and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Cancer Vaccines and Antibodies.

    To find out more about Triple Analysis: Leukemia, Cancer Vaccines and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Cancer Vaccines and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adaptimmune
Adherex
Advaxis
AEgera
Affibody
Affimed Therapeutics
Affitech
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Algeta
AlphaVax
ALSP
Altor BioScience
Ambit Biosciences
Amgen
Amorfix Life Sciences
Antisoma
Anza Therapeutics
Aphios
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Argos Therapeutics
Ariad
Arno Therapeutics
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Berkeley Lab
Bio-Path Holdings
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioInvent
Biolex
BioLineRx
BioNTech
BioSante
Biosceptre
Biostar
Biotecnol
Biotest
Bioton
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Advances
Cancer Innovations
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CSL
Curacyte
CuraGen
CureTech
CureVac
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dompe
Dong-A
Dr Reddy’s
Dyax
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Ergon Pharmaceuticals
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gemin X Biotechnologies
Gene Techno Science
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
Genomic Systems
GenPat77
Genta
Genticel
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
GlycoMimetics
Glycotope
Gradalis
Green Cross
Hanmi
Hawthorn Pharmaceuticals
Hayashibara
Heat Biologics
Heber Biotec
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
IMED
immatics biotechnologies
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
Immutep
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kaketsuken
KaloBios
Kanisa
Kinex
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
Medarex
MediGene
MedImmune
Memgen
Menarini
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Momotaro-Gene
Mycenax
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
NIH
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novogen
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Paladin Labs
Panacea
PanGenetics
Patrys
Pepscan Therapeutics
Peptagen
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Philogen
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
Protherics
Radient Pharmaceuticals
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Reliance Life Sciences
responsif
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shanghai CP Guojian
Shenogen
Shionogi
Shire
Sidus
Southern Research Institute
Spirogen
Stainwei Biotech
Stemline Therapeutics
Sunol Molecular
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Synta Pharmaceuticals
Syntrix
Tactic Pharma
Takeda
Talon Therapeutics
Tamir Biotechnology
TapImmune
Targa Therapeutics
TargeGen
TeGenero
Teva
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
Valeant
VasGene Therapeutics
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viragen
Virionics
ViroMed
Viventia Biotech
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yamasa Corporation
YM BioSciences
Zenotech
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
adecatumumab
ADXS11-001
AE-37
aflibercept
AGS-003
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
amonafide malate
amsacrine
ANZ-207
astuprotimut-r
Auto TAG vaccine
AV-299
AVX-701
barasertib
belagenpumatucel-L
belimumab
belinostat
bevacizumab
BHQ880
bisantrene
blinatumomab
BMS-663513
BMS-936558
bosutinib
BP-GMAX-CD1
brentuximab vedotin
BT-062
BV-NSCLC-001
carlumab
catumaxomab
CB-10-01
CDX-1307
CDX-1401
cetuximab
CG-201
cixutumumab
cladribine
clofarabine
CMAB302
CMAB304
conatumumab
CreaVax-PC
CSF-GM
CT-011
CV-9103
CV-9201
CVac
cytarabine ocfosfate
cytarabine, injectable
dalotuzumab
daratumumab
dasatinib
daunorubicin
DCVax-prostate
decitabine
denosumab
E-75
elacytarabine
elotuzumab
EMD-273063
EMD525797
emepepimut-S
enocitabine
epratuzumab
epratuzumab-Y90
ertumaxomab
farletuzumab
figitumumab
fresolimumab
galiximab
ganitumab
gemtuzumab ozogamicin
GI-4000
girentuximab
glembatumumab vedotin
GS-6634
GSK-2130579A
GV-1001
GVAX
GVX-3322
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
HS-110
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
ICT-107
idarubicin
imatinib mesilate
imMucin
IMO-2055
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukin-12
intetumumab
IPH-2102
ipilimumab
iratumumab
ISA-P53-01
JX-594
L19-TNFalpha
lestaurtinib
leukemia vaccine
lintuzumab
LIP-131I
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDX-1379
MEDI-551
MEDI-573
MGN-1601
midostaurin
milatuzumab
milatuzumab-doxorubicin
mitoxantrone
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
moxetumomab pasudotox
MVA-BN Her-2 vaccine
naptumomab estafenatox
natalizumab
necitumumab
nilotinib
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaratumab
ON-01910
onartuzumab
OncoVAX
Onyvax-105
oregovomab
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
panitumumab
PAT-SC1
peginterferon alfa-2b
pentostatin
pertuzumab
PF-4856884
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
ramucirumab
razoxane
Reditux
Reximmune-C
RG-7160
rhIFN-alpha
rilotumumab
rindopepimut
rintatolimod
rituximab
robatumumab
romiplostim
S-488410
samalizumab
SAR-3419
SCIB-1
siltuximab
sipuleucel-T
sobuzoxane
sotatercept
Survivac
Sym-004
tamibarotene
Tenarad
teniposide
TG-4010
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tipifarnib
tocilizumab
TRC-105
tremelimumab
TroVax
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
velimogene aliplasmid
veltuzumab
verpasep caltespen
vitespen
volociximab
vosaroxin
VX-001
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Cancer Vaccines and Antibodies.
    To find out more about Triple Analysis: Leukemia, Cancer Vaccines and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Cancer Vaccines and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Pancreatic Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Breast Cancer, Apoptosis and Angiogenesis
This triple analysis focuses on cancer drug development strategies in Breast Cancer and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Target Atlas in Oncology Drug Development: Major Tumor Types
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More


Triple Analysis: Colorectal Cancer, Lung Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the compound strategy of Antibodies. Learn More